Claims-based reconstruction of the pancreatic cancer care pathway links centralization of care to survival

Pancreatic cancer is one of the most formidable challenges in modern medicine, known for its aggressive nature and the difficulty of treating it once symptoms appear. Because the disease often progresses silently, by the time a patient feels pain, loses weight, or develops jaundice, the cancer may have already spread. In countries with advanced healthcare systems, the standard approach to managing such a complex illness involves two main strategies: gathering a team of different specialists to review the case together, and ensuring the patient receives care at a hospital with high volumes of experience. The first strategy, known as a multidisciplinary team review, brings together surgeons, oncologists, and radiologists to decide the best path forward. The second, centralization of care, suggests that patients do better when treated at specialized centers that handle many similar cases, rather than at smaller local hospitals. While these ideas are widely accepted in theory, it has been difficult to prove in real-world settings whether they actually extend a patient's life, or if they simply add delays to the treatment process.

To answer these questions, researchers in the Czech Republic turned to a vast digital record of patient care. They analyzed anonymized data from health insurance claims covering roughly 17 percent of all patients diagnosed with pancreatic cancer in the country between 2018 and 2020. This approach allowed them to reconstruct the entire journey of 1,255 individuals, from the moment their cancer was first detected by imaging or tissue testing until they either passed away or the study period ended. The team did not just look at whether patients received treatment; they traced the specific sequence of events. They wanted to know if having a team of specialists discuss the case before treatment began made a difference, and whether being treated at a large, specialized cancer center improved survival compared to treatment at other hospitals. They also tracked how long it took for patients to move from diagnosis to their first treatment, whether that was surgery, chemotherapy, or radiation.

The study revealed a stark reality about the current state of care. More than one-fifth of the patients in the group died without receiving any treatment at all, a finding that aligns with the known difficulty of treating this disease in its advanced stages. Among those who did receive treatment, the researchers found that the organization of care mattered significantly. Patients who were treated at a complex oncological center—a specialized hospital with extensive resources and experience—lived longer than those treated elsewhere. After adjusting for factors like age and the type of treatment received, the data showed that care at these specialized centers was linked to a clear survival advantage. In plain terms, the median survival time for patients at these centers was 532 days, compared to 394 days for those treated at non-specialized facilities. This suggests that the concentration of expertise and resources in one place provides a tangible benefit to the patient.

However, the story of the multidisciplinary team review was more complicated. While guidelines recommend that every patient should be reviewed by a team of specialists before treatment begins, the data showed that this happened for less than half of the patients. Only 47 percent of those who received treatment had a recorded team review. Surprisingly, when the researchers looked at the survival rates, they did not find a statistically significant link between having a team review and living longer. Patients who were discussed by a team did not live significantly longer than those who were not, once other factors were taken into account. This does not mean the team review is useless; rather, it suggests that the benefit might be harder to measure in this type of data, or that the review process is often reserved for patients who are already in better condition. The researchers noted that the time from diagnosis to treatment was slightly longer for patients who went through a team review, but this delay was not associated with worse outcomes.

The study also confirmed what many doctors have long suspected: surgery offers the best chance for a longer life, but it is an option for very few. Only about 36 percent of the treated patients underwent surgery as their first line of defense, while the majority received chemotherapy. Those who had surgery lived significantly longer than those who did not, with a median survival time of over three years for some, compared to roughly one year for those treated with chemotherapy alone. Yet, even among those who had surgery, the researchers found that the type of hospital mattered. The survival benefit of surgery was maintained regardless of the setting, but the overall system of care at specialized centers appeared to support better outcomes across the board, including for patients receiving chemotherapy.

The researchers were careful to note the limits of their work. Because they relied on insurance records, they did not have detailed information on the specific stage of the cancer for every patient, nor did they know the overall health or physical condition of the individuals before they started treatment. This means they could not prove that the specialized centers caused the longer lives, only that the two were linked. It is possible that patients who were healthier or had less advanced disease were more likely to be sent to these centers in the first place. Despite these limitations, the findings offer a clear picture of how pancreatic cancer care is currently delivered in the Czech Republic. It shows that while the ideal of a team-based approach is not yet fully realized, the centralization of care at specialized centers is a powerful factor in helping patients live longer. The study underscores that how care is organized is just as critical as the treatment itself, highlighting a need to ensure more patients reach the specialized centers where they have the best chance of survival.